EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Biomarkers and advances in AML-MRC: from bench to bedside

Fanlin Meng, Zahraa Al-Khafaji, Khursheed Muzammil, Ehsan Sarbazjoda, Mohammad Navid Khaksari, Alireza Bayani, Hamed Soleimani Samarkhazan

Annals of Hematology · 2026

DOI: 10.1007/s00277-026-06805-8 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Annals of Hematology, 2026. Verfasst von Fanlin Meng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Biomarkers, Tumor, Myelodysplastic Syndromes. Die Arbeit nennt 227 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) represents a high-risk subtype of AML, characterized by poor prognosis and limited therapeutic options. Recent updates in the WHO and ICC classifications have redefined AML-MRC, emphasizing molecular and cytogenetic criteria over morphological features alone. This review provides a comprehensive overview of the pathogenesis, key biomarkers, and diagnostic innovations in AML-MRC, highlighting the role of genetic mutations (e.g., TP53, RUNX1, and splicing factors), cytogenetic abnormalities, and immune microenvironment alterations. We explore advanced diagnostic techniques such as next-generation sequencing (NGS), minimal residual disease (MRD) monitoring, and functional precision medicine (FPM), which are revolutionizing disease stratification and treatment selection. Additionally, we discuss emerging therapies, including CPX-351, hypomethylating agents (HMAs), targeted inhibitors (e.g., FLT3 and IDH1/2 inhibitors), and immunotherapies, while addressing the challenges of treatment resistance and relapse. The integration of multi-omics technologies and liquid biopsies offers promising avenues for personalized medicine, enabling dynamic monitoring and tailored therapeutic strategies. Finally, we outline future directions, emphasizing the potential of artificial intelligence and collaborative efforts to overcome current limitations and improve patient outcomes. This review underscores the importance of precision medicine in transforming the management of AML-MRC, bridging the gap between bench research and clinical application.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteBiomarkers, TumorMyelodysplastic SyndromesHumansPrecision MedicineNeoplasm, ResidualHigh-Throughput Nucleotide SequencingMutationPrognosis

Stichwörter der Autor:innen

AML-MRCBiomarkersNext-generation sequencingPrecision medicineTargeted therapy

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Emergency, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
  • College of Pharmacy the Islamic University, Najaf, Iraq.
  • Department of Medical Analysis, Medical Laboratory Technique College the Islamic University of Al Diwaniyah, Al Diwaniyah, Iraq.
  • Department of Medical Analysis, Medical Laboratory Technique College the Islamic University of Babylon, Babylon, Iraq.
  • Central Labs, King Khalid University, AlQura'a, Abha, P.O., Box 960, Saudi Arabia.
  • Department of Public Health, College of Applied Medical Sciences, Khamis Mushait Campus, King Khalid University,, 62561, Abha, Saudi Arabia.

Zitieren

APA

Meng, F., Al-Khafaji, Z., Muzammil, K., Sarbazjoda, E., Khaksari, M. N., Bayani, A., & Soleimani Samarkhazan, H. (2026). Biomarkers and advances in AML-MRC: from bench to bedside. Annals of Hematology. https://doi.org/10.1007/s00277-026-06805-8

Vancouver

Meng F, Al-Khafaji Z, Muzammil K, Sarbazjoda E, Khaksari MN, Bayani A, et al. Biomarkers and advances in AML-MRC: from bench to bedside. Annals of Hematology. 2026. doi:10.1007/s00277-026-06805-8

BibTeX
@article{Meng2026,
  author = {Meng, Fanlin and Al-Khafaji, Zahraa and Muzammil, Khursheed and Sarbazjoda, Ehsan and Khaksari, Mohammad Navid and Bayani, Alireza and Soleimani Samarkhazan, Hamed},
  title = {Biomarkers and advances in AML-MRC: from bench to bedside},
  journal = {Annals of Hematology},
  year = {2026},
  doi = {10.1007/s00277-026-06805-8}
}
Kostenlos starten →